Max Chat
Calendrier des promotions Avadel Pharmaceuticals plc
Calendrier avancé
Graphique simple
À propos de l'entreprise Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc работает как биофармацевтическая компания в США. Его ведущим продуктом-кандидатом является LUMRYZ, состав оксибата натрия, который находится в фазе 3 клинических испытаний для лечения чрезмерной дневной сонливости или катаплексии у взрослых с нарколепсией. Компания, ранее известная как Flamel Technologies SA, сменила название на Avadel Pharmaceuticals plc в январе 2017 года. Avadel Pharmaceuticals plc была зарегистрирована в 2015 году, ее штаб-квартира находится в Дублине, Ирландия.
Paramètres de base
IPO date
1996-06-07
ISIN
US05337M1045
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 5.91 | 2 |
| P/BV | 13.53 | 1 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -29.69 | 0 |
| ROE | -60.44 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.0479 | 10 |
| Debt/Ratio | 0.0104 | 10 |
| Debt/Equity | 1.22 | 8 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 185.6 | 10 |
| Rentabilité Ebitda, % | 12.53 | 2 |
| Rentabilité EPS, % | -501.24 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 9.57 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 10.07 $ | 0 $ | 0 $ | -4.97 % | 0 % | 0 % |
| common.calendar.number_days.30d | 9.13 $ | 9.57 $ | 9.57 $ | +4.82 % | 0 % | 0 % |
| common.calendar.number_days.90d | 7.13 $ | 7.91 $ | 10.23 $ | +34.22 % | 0 % | 0 % |
| common.calendar.number_days.180d | 8.33 $ | 6.59 $ | 10.23 $ | +14.89 % | 0 % | 0 % |
| common.calendar.number_days.1y | 14.86 $ | 6.59 $ | 16.91 $ | -35.6 % | 0 % | 0 % |
| common.calendar.number_days.3y | 6.59 $ | 4.28 $ | 18.82 $ | +45.22 % | 0 % | 0 % |
| common.calendar.number_days.5y | 8.24 $ | 1.07 $ | 18.82 $ | +16.14 % | 0 % | 0 % |
| common.calendar.number_days.10y | 1.07 $ | 1.07 $ | 25.69 $ | +894.39 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 7.49 $ | 6.59 $ | 11.06 $ | +27.77 % | 0 % | 0 % |
Contenu dans l'ETF
ETF | Partager, % | Rentabilité pour l'année, % | Commission, % |
| Future Tech ETF | 0.12494 | 479.5 | 0.35 |
| Principal Healthcare Innovators ETF | 0.12494 | -3.92 | 0.35 |
| iShares Morningstar Small-Cap Growth ETF | 0.0533 | 570.49 | 0.06 |
| iShares Morningstar Small-Cap ETF | 0.0271 | 301.34 | 0.25 |
| 0,08 | 336,85 | 0,25 |
|---|
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Mr. Gregory J. Divis Jr. | CEO & Director | 753.69k | 1967 (58 années) |
| Mr. Thomas S. McHugh | Senior VP, Principal Financial and Accounting Officer & CFO | 526k | 1965 (60 années) |
| Mr. Richard J. Kim | Chief Commercial Officer | 548.44k | 1969 (56 années) |
| Mr. Jerad G. Seurer | General Counsel & Company Secretary | N/A | 1973 (52 année) |
| Mr. Gregory J. Davis | VP of Corporate and Business Development | N/A | 1965 (60 années) |
| Mr. Mark W. Elrod | Vice President of Sales | N/A | |
| Ms. Angie Woods | Vice President of People & Culture | N/A | |
| Dr. Jordan S. Dubow M.D. | Consultant | 727.93k | 1978 (47 années) |
| Dr. Jason M. Vaughn | Senior Vice President of Technical Operations | N/A | |
| Ms. Jennifer Gudeman PharmD | Senior Vice President of Medical & Clinical Affairs | N/A |
Informations sur l'entreprise
Adresse: Ireland, Dublin, 10 Earlsfort Terrace - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.avadel.com
Site web: https://www.avadel.com
